Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Director Ra Capital Management, L.P. Purchases 162,539 Shares

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Director Ra Capital Management, L.P. bought 162,539 shares of the business’s stock in a transaction dated Wednesday, May 14th. The stock was purchased at an average price of $0.98 per share, for a total transaction of $159,288.22. Following the acquisition, the director now directly owns 6,237,482 shares of the company’s stock, valued at approximately $6,112,732.36. The trade was a 2.68% increase in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Ra Capital Management, L.P. also recently made the following trade(s):

• On Monday, May 12th, Ra Capital Management, L.P. purchased 320,913 shares of Werewolf Therapeutics stock. The shares were acquired at an average cost of $0.86 per share, with a total value of $275,985.18.

Werewolf Therapeutics Stock Down 2.9%

NASDAQ:HOWL opened at $0.99 on Thursday. The company has a debt-to-equity ratio of 0.29, a current ratio of 10.10 and a quick ratio of 10.10. The firm’s 50-day moving average price is $0.93 and its 200-day moving average price is $1.40. The company has a market capitalization of $44.43 million, a PE ratio of -0.65 and a beta of 0.48. Werewolf Therapeutics, Inc. has a 1-year low of $0.60 and a 1-year high of $5.73.

Werewolf Therapeutics (NASDAQ:HOWL) last posted its quarterly earnings data on Thursday, May 8th. The company reported ($0.40) EPS for the quarter, topping the consensus estimate of ($0.44) by $0.04. Werewolf Therapeutics had a negative net margin of 578.80% and a negative return on equity of 58.83%. On average, equities analysts predict that Werewolf Therapeutics, Inc. will post -1.56 EPS for the current fiscal year.

Institutional Trading of Werewolf Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in HOWL. Barclays PLC raised its stake in Werewolf Therapeutics by 130.1% during the third quarter. Barclays PLC now owns 54,810 shares of the company’s stock valued at $116,000 after buying an additional 30,990 shares during the last quarter. Bank of New York Mellon Corp increased its holdings in shares of Werewolf Therapeutics by 23.1% during the fourth quarter. Bank of New York Mellon Corp now owns 71,300 shares of the company’s stock valued at $106,000 after acquiring an additional 13,372 shares in the last quarter. Geode Capital Management LLC increased its holdings in shares of Werewolf Therapeutics by 2.4% during the fourth quarter. Geode Capital Management LLC now owns 702,558 shares of the company’s stock valued at $1,040,000 after acquiring an additional 16,569 shares in the last quarter. JPMorgan Chase & Co. raised its position in shares of Werewolf Therapeutics by 372.4% in the 4th quarter. JPMorgan Chase & Co. now owns 62,928 shares of the company’s stock worth $93,000 after purchasing an additional 49,608 shares during the last quarter. Finally, Levin Capital Strategies L.P. bought a new position in Werewolf Therapeutics in the 4th quarter worth about $74,000. Hedge funds and other institutional investors own 64.84% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts recently commented on HOWL shares. Wedbush dropped their price target on Werewolf Therapeutics from $8.00 to $6.00 and set an “outperform” rating for the company in a research note on Friday, May 9th. HC Wainwright reissued a “buy” rating and issued a $15.00 target price on shares of Werewolf Therapeutics in a research report on Wednesday, March 12th.

Werewolf Therapeutics Company Profile

Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.